Evidence map›Paper›PMID 41104257›Full record

ArticleIranian journal of pharmaceutical research : IJPR

In Silico Analysis of Tat Exons to Increase the Efficacy of a Nef-Tat-based HIV-1 Vaccine Candidate.

Leila Sadeghi, Fatemeh Heidarnejad, Azam Bolhassani, Elham Mohit, Parisa Moradi Pordanjani

Abstract read
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Leila SadeghiDepartment of Hepatitis, AIDS and Blood-Borne Diseases, Pasteur Institute of Iran, Tehran, Iran.
Fatemeh HeidarnejadDepartment of Hepatitis, AIDS and Blood-Borne Diseases, Pasteur Institute of Iran, Tehran, Iran.
Azam BolhassaniDepartment of Hepatitis, AIDS and Blood-Borne Diseases, Pasteur Institute of Iran, Tehran, Iran.
Elham MohitDepartment of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Parisa Moradi PordanjaniDepartment of Hepatitis, AIDS and Blood-Borne Diseases, Pasteur Institute of Iran, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The global human immunodeficiency virus HIV/AIDS pandemic persists without complete eradication. Developing a safe and effective vaccine remains the most promising approach, but ongoing clinical trials have been unsuccessful due to the vaccines' inability to stimulate robust immunity. Objectives: The present research endeavor proposes an innovative therapeutic vaccine by employing immunoinformatics strategies. Herein, we aimed to compare the efficiency of the whole sequence of Tat Methods: First, the secondary structures of both fusion proteins were predicted. Then, 3D models of the constructs were refined, and their physicochemical properties were determined. After analysis of toxicity, allergenicity, and antigenicity of constructs, the formation of ligand (constructs)-receptor (TLR-2 to TLR-5, and TLR-7 to TLR-9) complexes was examined using the ClusPro and HDOCK servers, and the highest scores of docking analysis were used for molecular dynamics (MDs) simulation. Finally, the JCat server was applied for codon optimization. Results: Our results indicated that both protein constructs were antigenic, non-allergenic, and capable of eliciting adaptive immune responses. The average values of radius of gyration (Rg) for Nef-Tat Conclusions: Generally, immunoinformatics studies showed the importance of Tat exon 1 in HIV-1 fusion vaccine design.

Indexed as

HIV-1Immunoinformatics AnalysisNefTatVaccine

Identifiers

PMID41104257
PMCPMC12523967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.